

Please amend the specification as follows:



[015] In accordance with the present invention, the targeted biological membranes include, but are not limited to, dermal membrane and mucosal membranes. The preferred membrane fusion proteins include saposin C as well as other proteins, polypeptide analogues or polypeptides derived from either saposin C, SEQ. ID .NO. 1, SEQ. ID. NO. 2, SEQ ID No. 3, SEQ. ID No. 4, SEQ ID No. 5 or SEQ ID No. 6. are and polypeptides of the formula:

h u Cys Glu h Cys Glu h h h Lys Glu h u Lys h h Asp Asn Asn Lys u Glu Lys Glu h h Asp h h Asp Lys h Cys u Lys h h, where h = hydrophobic amino acids, including, Val, Leu, Ile, Met, Pro, Phe, and Ala; and u = uncharged polar amino acids, including, Thr, Ser, Tyr, Gly, Gln, and Asn., and mixtures thereof.